Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections
The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
1. A method to cure HCV in a human, comprising providing a therapeutically effective amount of a compound of the formula
or its pharmaceutically acceptable salt optionally in a pharmaceutically acceptable carrier, wherein cure means that HCV antibodies or HCV virus can no longer be detected in the human's blood or plasma.
2. The method of claim 1 , wherein the HCV virus can no longer be detected in the human's blood.
3. The method of claim 1 , wherein the HCV antibodies can no longer be detected in the human's blood.
4. The method of claim 1 , wherein the HCV virus can no longer be detected in the human's plasma.
5. The method of claim 1 , wherein the HCV antibodies can no longer be detected in the human's plasma.
6. The method of claim 1 , wherein a sustained virologic response (SVR) is achieved in the human.